Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine versus olanzapine for prevention of chemotherapy-induced nausea and vomiting
IRCT20090613002027N22Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirtazapine and olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Severity of nausea and vomiting. Started Oct 2024; status: completed.
02
Drugs
mirtazapineolanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20090613002027N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090613002027N22.